{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:09:46Z","timestamp":1789088986584,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medj.2026.101230","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:40:38Z","timestamp":1785336038000},"page":"101230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rewriting the sarcomere: Gene therapy approaches for hypertrophic cardiomyopathy from bench to bedside"],"prefix":"10.1016","volume":"7","author":[{"given":"Susan K.","family":"Keen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind Y.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101230_bib1","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Members","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.medj.2026.101230_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.272.5262.731","article-title":"A mouse model of familial hypertrophic cardiomyopathy","volume":"272","author":"Geisterfer-Lowrance","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.medj.2026.101230_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101230_bib4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/ehjdh\/ztaf086","article-title":"Artificial intelligence applications in hypertrophic cardiomyopathy: turns and loopholes","volume":"6","author":"Panichella","year":"2025","journal-title":"European Heart Journal - Digital Health"},{"key":"10.1016\/j.medj.2026.101230_bib5","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacep.2025.02.024","article-title":"Real-World Artificial Intelligence-Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy","volume":"11","author":"Desai","year":"2025","journal-title":"JACC. Clin. Electrophysiol."},{"key":"10.1016\/j.medj.2026.101230_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2026.101230_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.medj.2026.101230_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/15353702211072453","article-title":"Allele-specific silencing by RNAi of R92Q and R173W mutations in cardiac troponin T","volume":"247","author":"Migliore","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.medj.2026.101230_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/emmm.201202168","article-title":"Rescue of cardiomyopathy through U7sn RNA-mediated exon skipping in Mybpc3-targeted knock-in mice","volume":"5","author":"Gedicke-Hornung","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.medj.2026.101230_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101230_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41434-023-00384-3","article-title":"Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy","volume":"30","author":"Nie","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.medj.2026.101230_bib12","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/cvr\/cvaf200","article-title":"First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1","volume":"121","author":"Desai","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.medj.2026.101230_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.cardfail.2024.10.398","volume":"31","author":"Haroldson","year":"2025","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.medj.2026.101230_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","article-title":"AAV9: PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy","volume":"4","author":"Wu","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.medj.2026.101230_bib15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9. LAMP2B gene therapy in Danon disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101230_bib16","article-title":"AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ:. Genomic and Precision Medicine"},{"key":"10.1016\/j.medj.2026.101230_bib17","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","article-title":"Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics","volume":"2","author":"Bradford","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.medj.2026.101230_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","article-title":"Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Kyriakopoulou","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.medj.2026.101230_bib19","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/hmg\/ddy427","article-title":"Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms","volume":"28","author":"Belbellaa","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.medj.2026.101230_bib20","first-page":"e471","article-title":"Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association","volume":"150","author":"Kim","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2026.101230_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/hum.2022.081","article-title":"Seroprevalence of adeno-associated virus neutralizing antibodies in males with Duchenne muscular dystrophy","volume":"34","author":"Verma","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.medj.2026.101230_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101230_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2026.101230_bib24","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2026.101230_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101230_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.medj.2026.101230_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101195","article-title":"Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74","volume":"32","author":"Potter","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.medj.2026.101230_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-021-00249-8","article-title":"Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy","volume":"10","author":"Gavriilaki","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101230_bib29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","article-title":"Hepatotoxicity in adeno-associated viral vector gene therapy","volume":"22","author":"Jagadisan","year":"2023","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.medj.2026.101230_bib30","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.medj.2026.101230_bib31","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2601608","article-title":"Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery","volume":"394","author":"Ahrens-Nicklas","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101230_bib32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.medj.2026.101230_bib33","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2026.101230_bib34","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:49:57Z","timestamp":1789087797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026002333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666634026002333"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101230","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rewriting the sarcomere: Gene therapy approaches for hypertrophic cardiomyopathy from bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101230"}}